EUVIMEDEUVIMED entdecken
CrossrefInfokarte

A murine model of amyloid‐enhanced tauopathy: Comparison of wild‐type and P301L‐tau

Dylan J. Finneran, Taylor Desjarlais, Brianna M. Jackman, Marcia N. Gordon, David Morgan

Alzheimer's & Dementia · 2026-10 · 22 (10)

DOI: 10.1002/alz.71788 ↗
AbstractBibliografische Angaben

Abstract

Abstract INTRODUCTION To optimize a model of amyloid‐enhanced tauopathy we compared wild‐type (WT) tau with P301L‐tau in a mouse with mature amyloid. METHODS Mice transgenic for amyloid precursor protein and presenilin‐1 (APP+PS1, A/P) were injected intravenously with adeno‐associated virus with capsid B10 (AAV.CAP‐B10) expressing either WT or P301L human tau. Mice were behaviorally assessed 5 and 8 months and tissue collected 9 months after injection. RESULTS A/P+WT and A/P+P301L groups were equivalently impaired in spatial learning and memory. A/P+WT mice had significantly greater tau hyperphosphorylation than A/P+P301L mice. However, A/P+P301L mice had greater deposition of phospho‐tau and formation of Gallyas‐positive neurofibrillary tangles (NFTs). DISCUSSION These data demonstrate that WT‐tau is more highly phosphorylated than P301L‐tau in the presence of amyloid in mouse brain. Furthermore, despite the lack of NFT pathology in A/P+WT mice, WT‐tau still caused cognitive impairment. The use of WT‐tau in this model may make it more translatable for pre‐clinical assessments of potential therapeutics for AD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →